Abstract
Intravascular large B-cell lymphoma (IVLBCL) is a rare form of diffuse LBCL characterized by preferential intravascular growth of malignant lymphocytes, aggressive behavior, and an often fatal course. IVLBCL usually affects elderly patients with poor performance status, elevated lactic dehydrogenase serum levels, anemia, and B symptoms. It displays some differences in clinical presentation among diverse geographical areas, mostly between patients diagnosed in Western countries and Japan. In addition, data from the literature suggest that pathologic diagnostic criteria as well as clinical features of this disease may be broader than described in current classification scheme(s). Under the sponsorship of the International Extranodal Lymphoma Study Group, clinicians and pathologists with interest in IVLBCL, coming from Western and Eastern countries, joined to reach a consensus on defining features as well as to focus on the most urgent unresolved issues in IVLBCL. To this end, a representative group of IVLBCL patients coming from both the aforementioned geographical areas were collectively analyzed. Additional features of IVLBCL were proposed both under clinical and pathologic stand points. At the meeting, it emerged that IVLBCL may have additional histopathologic/cytologic definition criteria with respect to those currently recommended, some clinical features are not randomly distributed worldwide, recent therapeutic approaches, such as anti-CD20-containing regimens, may improve outcome, and kidney, spleen, and liver involvement may show peculiar histopathologic features. Finally, a provisional practical diagnostic approach to hemophagocytosis-associated patients and a proposal for the most useful criteria in the settings of differential diagnosis are included.
| Original language | English |
|---|---|
| Pages (from-to) | 3168-3173 |
| Number of pages | 6 |
| Journal | Journal of Clinical Oncology |
| Volume | 25 |
| Issue number | 21 |
| DOIs | |
| Publication status | Published - Jul 20 2007 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Definition, diagnosis, and management of intravascular large B-cell lymphoma : Proposals and perspectives from an international consensus meeting. / Ponzoni, Maurilio; Ferreri, Andrés J M; Campo, Elías; Facchetti, Fabio; Mazzucchelli, Luca; Yoshino, Tadashi; Murase, Takuhei; Pileri, Stefano A.; Doglioni, Claudio; Zucca, Emanuele; Cavalli, Franco; Nakamura, Shigeo.
In: Journal of Clinical Oncology, Vol. 25, No. 21, 20.07.2007, p. 3168-3173.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Definition, diagnosis, and management of intravascular large B-cell lymphoma
T2 - Proposals and perspectives from an international consensus meeting
AU - Ponzoni, Maurilio
AU - Ferreri, Andrés J M
AU - Campo, Elías
AU - Facchetti, Fabio
AU - Mazzucchelli, Luca
AU - Yoshino, Tadashi
AU - Murase, Takuhei
AU - Pileri, Stefano A.
AU - Doglioni, Claudio
AU - Zucca, Emanuele
AU - Cavalli, Franco
AU - Nakamura, Shigeo
PY - 2007/7/20
Y1 - 2007/7/20
N2 - Intravascular large B-cell lymphoma (IVLBCL) is a rare form of diffuse LBCL characterized by preferential intravascular growth of malignant lymphocytes, aggressive behavior, and an often fatal course. IVLBCL usually affects elderly patients with poor performance status, elevated lactic dehydrogenase serum levels, anemia, and B symptoms. It displays some differences in clinical presentation among diverse geographical areas, mostly between patients diagnosed in Western countries and Japan. In addition, data from the literature suggest that pathologic diagnostic criteria as well as clinical features of this disease may be broader than described in current classification scheme(s). Under the sponsorship of the International Extranodal Lymphoma Study Group, clinicians and pathologists with interest in IVLBCL, coming from Western and Eastern countries, joined to reach a consensus on defining features as well as to focus on the most urgent unresolved issues in IVLBCL. To this end, a representative group of IVLBCL patients coming from both the aforementioned geographical areas were collectively analyzed. Additional features of IVLBCL were proposed both under clinical and pathologic stand points. At the meeting, it emerged that IVLBCL may have additional histopathologic/cytologic definition criteria with respect to those currently recommended, some clinical features are not randomly distributed worldwide, recent therapeutic approaches, such as anti-CD20-containing regimens, may improve outcome, and kidney, spleen, and liver involvement may show peculiar histopathologic features. Finally, a provisional practical diagnostic approach to hemophagocytosis-associated patients and a proposal for the most useful criteria in the settings of differential diagnosis are included.
AB - Intravascular large B-cell lymphoma (IVLBCL) is a rare form of diffuse LBCL characterized by preferential intravascular growth of malignant lymphocytes, aggressive behavior, and an often fatal course. IVLBCL usually affects elderly patients with poor performance status, elevated lactic dehydrogenase serum levels, anemia, and B symptoms. It displays some differences in clinical presentation among diverse geographical areas, mostly between patients diagnosed in Western countries and Japan. In addition, data from the literature suggest that pathologic diagnostic criteria as well as clinical features of this disease may be broader than described in current classification scheme(s). Under the sponsorship of the International Extranodal Lymphoma Study Group, clinicians and pathologists with interest in IVLBCL, coming from Western and Eastern countries, joined to reach a consensus on defining features as well as to focus on the most urgent unresolved issues in IVLBCL. To this end, a representative group of IVLBCL patients coming from both the aforementioned geographical areas were collectively analyzed. Additional features of IVLBCL were proposed both under clinical and pathologic stand points. At the meeting, it emerged that IVLBCL may have additional histopathologic/cytologic definition criteria with respect to those currently recommended, some clinical features are not randomly distributed worldwide, recent therapeutic approaches, such as anti-CD20-containing regimens, may improve outcome, and kidney, spleen, and liver involvement may show peculiar histopathologic features. Finally, a provisional practical diagnostic approach to hemophagocytosis-associated patients and a proposal for the most useful criteria in the settings of differential diagnosis are included.
UR - http://www.scopus.com/inward/record.url?scp=34547661620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547661620&partnerID=8YFLogxK
U2 - 10.1200/JCO.2006.08.2313
DO - 10.1200/JCO.2006.08.2313
M3 - Article
C2 - 17577023
AN - SCOPUS:34547661620
VL - 25
SP - 3168
EP - 3173
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 21
ER -